Johnson & Johnson’s (JNJ) consumer healthcare segment includes baby care, oral care, skin care, over-the-counter products, women’s health, and wound care franchises.
Johnson & Johnson’s (JNJ) pharmaceutical segment comprises of its Immunology, Infectious Disease, Neuroscience, Oncology, and Cardiovascular and Metabolics franchises.
On an annual basis, Johnson & Johnson’s revenues have increased over the past few years following the restructuring of its business segments and strong performance of some of its key products.
Johnson & Johnson’s valuation multiple was opposite to the industry’s trend until mid-2013, and it has followed the industry’s overall trend since mid-2013.
Johnson & Johnson (JNJ) has surpassed all estimates for earnings per share (or EPS) in the past, and analysts estimate JNJ to generate an EPS of $1.43 in 4Q15.
Johnson & Johnson (JNJ) has restructured its business over the last few years and divested some low profitability products in order to improve its profitability.
Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.
After the release of its fiscal 3Q15 earnings results on October 28, 2015, Amgen (AMGN) traded at a PE (price-to-earnings) ratio of 12.9x–13.7x.
In 2015, Amgen (AMGN) managed to launch six new products in the US market. The company expects its cardiovascular drug Repatha to become a blockbuster drug.
Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.
Wall Street analysts projected a gradual fall in the revenue for Amgen’s (AMGN) blockbuster inflammation drug Enbrel in 4Q15.
On January 26, 2016, Amgen will announce its 4Q15 earnings for the period ending on December 31, 2015. Wall Street expects Amgen’s 4Q15 revenue to be ~$5.5 billion.
Based on the earnings calendar published by Nasdaq, Amgen (AMGN) is expected to release its 4Q15 and full-year 2015 earnings results on January 26, 2016.
Falling aluminum prices could dent the 4Q15 earnings of Alcoa’s Primary Metals segment. Alcoa’s Alumina segment could also put a hole in its 4Q15 earnings.
Several steel companies have commented on the current operating environment and industry outlook.
AK Steel expects to post a loss per share of $0.33–$0.38. The 4Q15 loss comes after AK Steel’s better-than-expected 3Q15 performance.
Nucor (NUE) and Steel Dynamics (STLD) released their 4Q15 earnings guidance on December 16 and December 17, respectively.
Steel companies have reduced their spot sales in response to depressed spot steel prices.
Steel Dynamics (STLD) and AK Steel (AKS) expect fewer shipments in 4Q15 than they had in the previous quarter.
Last week, several steel companies released their 4Q15 earnings guidance.